CD274 and non-small cell lung carcinoma: Whereas, in CheckMate 568 (Nivolumab plus Ipilimumab in advanced NSCLC), the higher ORR was noted for patients with TMB-high tumors (≥10 mu/Mb using the F1CDx platform) regardless of PD-L1 status [90].